ARCHIVES

Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Cancer Documentary Provides Argument for Increased Funding

May 23, 1986

Phase III Tumor Treating Fields Trial Halted Following Positive Results in Interim Analysis

November 28, 2014

FDA Publishes Parallel Track Rules, Accelerated Drug Approval Initiative

April 25, 1992

In Brief; NCAB Goes Along With NCI Staff In Funding EORTC Statistical Center Grant Out Of Priority Sequence

November 20, 1981

Definitions, New Categories Of Centers Suggested By Cantril

July 2, 1976

CCI Will Tackle Reimbursement Issue

May 16, 1980